SpectraCure (publ) will present results from the company's Phase 1 study at the International Photodynamic Association World Congress arranged June 28th – July 4th in Boston, Massachusetts, USA. The presentation will be held by Johannes Swartling, CTO.
– We look forward to presenting the results from the Phase 1 study at a world conference and it is very exciting to share the successful result from SpectraCure's Phase 1 study with world-leading clinical researchers, says Masoud Khayyami, CEO of SpectraCure.
The patient treatments in the Phase 1 study are completed, patient follow-up will be performed until all patients have undergone a biopsy one year after treatment.
SpectraCure initiated patient treatments in the following Phase 2 study together with its clinical partners during the month of April. The purpose of the Phase 2 study is to show that the method is safe to use and that it has clinical effect, with a larger statistical basis than in the Phase 1 study.
